In the Australian pharmaceutical industry, there were 4 M&A deals announced in Q3 2023, worth a total value of $227.7m, according to GlobalData’s Deals Database. The $226.6m acquisition of Healthia by Harold BidCo was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Australia decreased by 72% in Q3 2023 compared with the previous quarter’s total of $802.6m and rose by 8363% as compared to Q3 2022. Related deal volume decreased by 56% in Q3 2023 versus the previous quarter and was 33% lower than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in Australia in Q3 2023 were EM Advisory; Goldman Sachs Group; Moelis & Co with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in Australia Q3 2023 were Baker & McKenzie; Clayton UTZ; Hall & Wilcox with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.